Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
16 slides from Angiodynamics's conference presentation, Jan 14, 2026
Slide 1: J.P. Morgan 44th Annual Healthcare Conference
J.P. Morgan 44th Annual Healthcare Conference January 14, 2026 Jim Clemmer, President & CEO
Slide 2: Forward looking statements
Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations,
Slide 3: AngioDynamics
AngioDynamics Our proven success positions us for sustained growth and profitability in key markets. 2020 - Today Today & Beyond Drove Performance and Built a More Dynamic Growth Positioned for Sustained Profitable Growth Focused Company Accelerating Commercial Investment Sharpened Portfolio Focus •
Slide 4: Unrivaled Innovation
Unrivaled Innovation Our synergistic portfolio is focused on providing comprehensive solutions to help treat patients within two of the largest global healthcare markets Cardiovascular Disease Cancer ARTERIAL VENOUS Med Tech Peripheral Artery Disease Venous Thromboembolism Prostate Care (PAD) (VTE)
Slide 5: Cardiovascular Arterial
Cardiovascular Arterial Since its launch in September 2020, Auryon has been used in nearly 150,000 procedures and surpassed $200M in cumulative sales MARKET DYNAMICS Peripheral Artery Disease (PAD) • Hospital market growth fuels ASP stability • New and expanded reimbursement coverage solidifies athe
Slide 6: Cardiovascular Venous
Cardiovascular Venous Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity MARKET DYNAMICS PE PE + DVT = Venous Thromboembolism (VTE) $2.4B • Mechanical Thrombectomy for PE is estimated to have penetrated ~20% of the TAM • Mechanical Thrombectomy for
Slide 7: Mechanical Thrombectomy
Mechanical Thrombectomy Proprietary funnel cannula technology with the ability to have aspiration and simultaneous reinfusion with AngioVac or off-circuit manual aspiration control with AlphaVac AlphaVac Indicated for Treatment of Pulmonary Embolism Aspiration & Simultaneous Reinfusion • Minimally i
Slide 8: APEX – AV Pivotal Study
APEX – AV Pivotal Study AlphaVac received FDA clearance for PE following APEX-AV study demonstrating efficacy and significantly improved reduction in clot burden vs. competitive technologies Number of Sites 25 US Sites Number of Patients 122 Timeline Oct. 2022 – Dec 2023 Significant reduction in the
Slide 9: Prostate Cancer
Prostate Cancer Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kind technology poised to change the standard of care of men with prostate cancer MARKET DYNAMICS Prostate Cancer is Prevalent, On the Rise & Debilitating Intermediate • The most diagnosed male cancer
Slide 10: Irreversible Electroporation (IRE)
Irreversible Electroporation (IRE) Preserves the underlying structure of tissue giving physicians a more precise tool Only IRE device FDA cleared for prostate tissue DECELLULARIZATION Destroys targeted tissue with precise Efficiently treats all segments of the prostate treatment margins. Easy clinic
Slide 11: PRESERVE Pivotal Study
PRESERVE Pivotal Study NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation Number of Sites 17 US Sites Number of Patients 121 Follow Up 12 Months Efficacy Safety 84% of patients
Slide 12: National Recognition for Oncology
National Recognition for Oncology Leveraging TIME and AARP to elevate awareness and credibility TIME’s Best Inventions of 2025 Marketing Partnership • Recognized as a top PRINT AD featured in AARP innovation in Medical & Magazine Healthcare (October/November “Medical Breakthroughs” issue) • Focus on
Slide 13: Strong Product & Clinical Pipeline
Strong Product & Clinical Pipeline Leveraging our leading platforms to fuel innovation, market expansion, and long-term shareholder value in key growth markets FY25 & Earlier FY26 – FY31 Platform $7.2B US TAM $10.9B US TAM Peripheral Artery Disease $800M US TAM IVL Indication DVT: $2.8B US TAM Coron
Slide 14: Compelling FY2026 Financial Outlook
Compelling FY2026 Financial Outlook Supported by balance sheet strength FY 2026 Net Sales ($M) FY 2026 Financial Guidance* $312 - $314 Prior Current Metric Action $293 Guidance Guidance Net Sales Increased $308 - $313M $312 - $314M +14 - 16% Med Tech Med Tech Net Sales Growth Unchanged +14 – 16% +14
Slide 15: AngioDynamics Investment Summary
AngioDynamics Investment Summary Attractive MedTech Platforms in High-Value Markets Our MedTech segment operates in large, growing clinical markets, supported by differentiated technologies and proven clinical outcomes. Demonstrated Execution and Portfolio Discipline We have a strong track record of
Slide 16: J.P. Morgan 44th Annual Healthcare Conference
J.P. Morgan 44th Annual Healthcare Conference January 14, 2026 Jim Clemmer, President & CEO
AngioDynamics — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix